Navigation Links
NSAIDs: Painkillers, inflammation inhibitors, anti-cancer drugs and new de-methylating agents
Date:3/26/2008

Researchers at the National Sun Yat-Sen University and Kaohsiung Medical University, Kaohsiung, Taiwan have revealed a new mechanism by which nonsteroidal anti-inflammatory drugs (NSAIDs) attenuate tumor invasion and metastasis. The research, to be published in the April 2008 issue of Experimental Biology and Medicine, provides new insights for the understanding of the anti-cancer effects of NSAIDs.

NSAIDs have been used for the suppression of pain and inflammation in the clinic for many years. The main targets of these drugs are cyclooxygenases (COXs) which play critical roles in maintaining physiological homeostasis, mediating inflammatory reactions and promoting tumorigenesis. However, COX-independent effects are also important for the inhibition of cancer development by NSAIDs. Indeed, NSAIDs are considered as a novel class of effective chemopreventive drugs.

The research team, led by Wen-Chun Hung, Dean of College of Science, National Sun Yat-Sen University, and a recent doctorial graduate Mei-Ren Pan and two collaborators Hui-Chiu Chang and Lea-Yea Chuang of Kaohsiung Medical University found that NSAIDs up-regulated several anti-metastatic genes including secreted protein acidic and rich in cysteine (SPARC), thrombospindin-1 (TSP-1), TSP-3 and tissue inhibitors of metalloproteinase-2 (TIMP-2) in human lung cancer cells. Our functional assay suggested that increases of SPARC and other anti-metastatic genes were important for NSAIDs to inhibit tumor invasion and metastasis said Wen-Chun Hung. More importantly, we elucidated the underlying mechanism and demonstrated that up-regulation of SPARC in human lung cancer cells was mediated via inhibition of DNA methyltransferases (DNMTs) expression and promoter de-methylation. This is the first report to show that NSAIDs may inhibit the expression of DNMTs to reverse promoter methylation and to reactivate gene transcription.

The researchers say that hypermethylation of tumor suppressor genes is frequently found in many types of human cancer and is a crucial step for tumorigenesis. Recently, a number of de-methylating agents have been reported to exhibit potent anti-cancer effects in vitro and in vivo. Therefore, these agents are considered to be useful for cancer therapy. As a matter of fact, two de-methylating drugs 5-Azacitidine and 5-Aza-2-deoxycytidine (decitabine) have been approved for the treatment of myelodysplastic syndromes, a heterogenous group of hematopoietic stem cell disorders that are multifactorial in their etiology. Hung says our results indicate that NSAIDs may function as de-methylating agents via inhibition of DNMTs and may provide a new strategy for the treatment or prevention of cancer. Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, agrees and said These unique findings by Dr. Hung and colleagues suggest an entirely new function for non-steroidal anti-inflamatory drugs in cancer therapy. This is an exciting advance for the field of Cancer biology.


'/>"/>

Contact: Dr. Wen-Chung Hung
hung1228@ms10.hinet.net
886-752-52000 x5817
Society for Experimental Biology and Medicine
Source:Eurekalert

Related medicine news :

1. Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
2. Sirion Therapeutics Receives NDA Acceptance and Priority Review From the FDA for Durezol(TM) in the Treatment of Postoperative Ocular Inflammation
3. A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
4. Overweight Hispanic children shown to have vascular inflammation
5. Anti-Inflammatory Drug Improves Glycemia, Lowers Inflammation in Obese, Young Adults
6. TNF-alpha antagonist stops inflammation-induced colon cancer in its tracks
7. Cell-death receptor links cancer susceptibility and inflammation
8. iNOS expression may links chronic biliary inflammation to malignant transformation
9. Diabetes Linked to Blood Vessel Inflammation
10. Low-carb diet reduces inflammation and blood saturated fat in metabolic syndrome
11. Researchers develop powerful tool to study the genetics of inflammation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, ... services in their Napa Valley office. The technique utilizes the body’s own healing ... Canales and Dr. Furnas, are part of only a select few cosmetic surgeons ...
(Date:2/5/2016)... ... ... US Sports Camps , official operators of Nike Yoga Camps, announces ... training. ChildLight Yoga Studio is centrally situated in the picturesque New England city of ... founder Lisa Flynn expresses her excitement, “We are thrilled to be partnering with US ...
(Date:2/5/2016)... ... February 05, 2016 , ... Boar’s Head Brand®, one of ... for this weekend’s Big Game. Take the stress out of your party preparation – ... guests happy at every stage of the game. , “The key to hosting a ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... CitiDent, announces that it is now welcoming orthodontist, Dr. Amanda Cheng, to ... a complete range of oral health care, including general dentistry, cosmetic treatments, periodontics, ...
(Date:2/5/2016)... ... February 05, 2016 , ... On June 9-10, Las ... continuing medical education (CME) event presented by the Association for Comprehensive Care in ... for ACCORD, whose mission is to provide education, tools, and resources to primary ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , February 5, 2016 Site ... Today, VoicePower Ltd - The Speech Recognition People, announced their latest ... to improve patient care, reduce turnaround times and to save the ... ,- VoicePower client since 2013 Challenge: --> ... --> - Six doctors ,- Wirral CCG ,- VoicePower ...
(Date:2/4/2016)... , Feb. 4, 2016  Edwards Lifesciences Corporation (NYSE: ... for structural heart disease and critical care monitoring, announced ... repurchase (ASR) agreement with Morgan Stanley & Co. LLC ... repurchase is part of the Company,s previously authorized program ... common stock.  --> ...
(Date:2/4/2016)... , Feb. 4, 2016  SciClone Pharmaceuticals, Inc. ... it has entered into a settlement agreement with ... fully resolving the SEC,s investigation into possible violations ... the terms of the settlement agreement, SciClone has ... including disgorgement, pre-judgment interest and a penalty.  This ...
Breaking Medicine Technology: